Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U24OD024957 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of New Mexico | OTHER |
| University of Vermont | OTHER |
| Avera Research Institute | UNKNOWN |
| National Institutes of Health (NIH) |
Not provided
Not provided
Not provided
Not provided
The INTACT trial is a multisite pilot feasibility study aimed at testing the effectiveness of the INTACT Intervention program in improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. The trial will enroll 20 birthing parent/infant dyads across three sites and will evaluate feasibility endpoints rather than clinical outcomes. The study duration is 22 months, including study start-up, enrollment and intervention, and data analysis and manuscript preparation.
The INTACT trial is designed to address the need for interventions to improve neurodevelopmental outcomes in infants exposed to cannabinoids in utero. It is a multi-site pilot study conducted across three Institutional Development Award (IDeA) States Pediatric Clinical Trials Network (ISPCTN) sites. The trial aims to evaluate the feasibility of the INTACT Intervention program, which focuses on training birthing parents in contingent responding to promote early language, cognitive, and social development in their infants.
The study intervention consists of 12 monthly INTACT intervention coaching sessions, each comprising online module completion followed by personalized coaching sessions with interventionists certified to deliver the Play and Learn Strategies (PALS) methodology, which forms the basis for the INTACT intervention. The online modules focus on strengthening effective parenting practices, while the coaching sessions guide birthing parents in contingent responding techniques, such as reading infant signals and responding with warm and sensitive behaviors. There are three objectives for this study, examining 1) Participant Recruitment, 2) Participant Completion, and 3) Participant Adherence.
Objective 1 examines if birthing parents can be recruited and enrolled in the study. The endpoint of this objective is the percentage of potential participants approached for the study that are consented and determined to be eligible for study participation.
Objective 2 evaluates participant completion, as measured by the percent of birthing parent/infant dyads that complete the coaching session scheduled when the child is 12 months of age.
Objective 3 evaluates the number of individual INTACT intervention coaching sessions completed.
The study duration is planned for 22 months, including 1-4 months for study development and start-up, 3 months for enrollment, 12 months for the intervention, and 3 months for data organization, clean-up, and manuscript preparation.
The INTACT trial will not assess clinical outcomes but will inform the design of a future larger-scale clinical trial to evaluate the effectiveness of the INTACT Intervention program in improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Personalized coaching sessions | Experimental | A novel program to train birthing parents in contingent responding with the goal of improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. 1 personalized coaching session per month for 12 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Play and Learn Strategies (PALS) Program | Behavioral | Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of approached participants that are eligible for study participation | Whether a potential participant approached for study participation will eventually be consented and determined to be eligible for study participation. | 3 months |
| Percentage of participants that complete their final visit | Whether a birthing parent/infant dyad will complete the final coaching session when the child is 12 months of age. | 12 months following enrollment |
| Percentage of participants that receive a sufficient number of coaching sessions | Whether a participant will complete the sufficient number of INTACT intervention coaching sessions, defined as completion of at least 8 out of 12 coaching sessions. | 12 months following enrollment |
Not provided
Not provided
Inclusion Criteria:
Birthing Parent
Infant
Exclusion Criteria:
Birthing Parent
Infant
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Song Ounpraseuth, PhD | Contact | (501) 686-5647 | STOunpraseuth@uams.edu | |
| Matthew Henry, MSc | Contact | (501) 686-5647 | mhenry3@uams.edu |
| Name | Affiliation | Role |
|---|---|---|
| Jessie Maxwell, MD | University of New Mexico | Principal Investigator |
| Leigh-Anne Cioffredi, MD | University of Vermont | Principal Investigator |
| Maria Barber, DO |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of New Mexico Health Sciences Center | Recruiting | Albuquerque | New Mexico | 87131 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40354465 | Derived | Maxwell JR, Cioffredi LA, Talavera-Barber MM, Henry M, Beauman S, Hittson A, McCoy M, Chassereau L, Jin J, Abraham PA, Fu LY, Raissy H, Snowden JN. The protocol for a pilot feasibility trial of Improving Neurodevelopmental ouTcomes After prenatal Cannabinoid in uTero exposure (INTACT) study for a multi-center trial. PLoS One. 2025 May 12;20(5):e0322035. doi: 10.1371/journal.pone.0322035. eCollection 2025. |
Not provided
Not provided
We will conduct this trial in accordance with the following publication and data sharing policies and regulations:
NIH Public Access Policy. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication.
ECHO ISPCTN Publications and Presentations Policy. It ensures accurate, responsible, and efficient communication of findings from ECHO ISPCTN clinical trials.
NIH Data Sharing Policy and the policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Resulting Information Submission Rule. Other researchers may request data from this trial by contacting Song Ounpraseugh, PhD, at the ISPCTN Data Coordinating and Operations Center (DCOC).
Per data sharing polices of NIH and the ISPCTN
to be announced
Not provided
Not provided
| ID | Term |
|---|---|
| D007859 | Learning Disabilities |
| D002658 | Developmental Disabilities |
| ID | Term |
|---|---|
| D003147 | Communication Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| NIH |
A single-arm pilot study to assess feasibility of study procedures.
Not provided
Not provided
Not provided
Not provided
|
| Avera Research Institute |
| Principal Investigator |
| Avera Research Institute | Recruiting | Sioux Falls | South Dakota | 57108 | United States |
|
| University of Vermont Medical Center | Recruiting | Burlington | Vermont | 05401 | United States |
|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |